Pressure for Provenge Approval

A prostate cancer patient group files suit, demanding an FDA green light of Dendreon's vaccine. Investors are on board, too

A group representing both prostate cancer patients and disgruntled investors is suing the Food & Drug Administration's commissioner and others involved in the agency's unexpected decision to disapprove a proposed vaccine called Provenge.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.